RECRUITING

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults. CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role. The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period. The study will consist of two periods: 1. A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit. 2. A Treatment Period of 36 weeks. On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck and shoulders. Participants may continue some other medications, but details need to be recorded. There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study. The total study duration for a participant will be up to 40 weeks (approximately 9 months).

Official Title

A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

Quick Facts

Study Start:2025-06-30
Study Completion:2027-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06937931

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. A clinical diagnosis of isolated Cervical Dystonia (CD) (idiopathic) characterized by dystonic symptoms localised to the head, neck, and shoulder areas with at least moderate severity at Screening and Baseline (Day 1) defined as:
  2. * (a) Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score ≥20
  3. * (b) TWSTRS-Severity subscale score ≥15
  4. * (c) TWSTRS-Disability subscale score ≥3
  5. * (d) TWSTRS-Pain subscale score ≥ 1
  6. 2. Treatment naïve or non-naïve to BoNT therapy for CD
  1. 1. Participants presenting with a swallowing disorder of any origin which might be exacerbated by BoNT treatment, such as:
  2. * (a) Grade 3 or 4 on the Dysphagia Severity Scale (severe dysphagia) with swallowing difficulties and requiring a change in diet.
  3. 2. Predominant anterocollis.
  4. 3. Predominant retrocollis.
  5. 4. Traumatic torticollis or tardive torticollis.
  6. 5. Marked limitation on passive range of motion that suggests cervical contractures or structural abnormality.

Contacts and Locations

Study Contact

Ipsen Clinical Study Enquiries
CONTACT
See e mail
clinical.trials@ipsen.com

Principal Investigator

Ipsen Medical Director
STUDY_DIRECTOR
Ipsen

Study Locations (Sites)

Parkinson's & Mvmt Disorders Inst
Fountain Valley, California, 92708
United States
Emory Brain Health Center
Atlanta, Georgia, 30329
United States
Quest Research Institute
Farmington Hills, Michigan, 48334
United States
Kingfisher Cooperative
Spokane, Washington, 99201
United States

Collaborators and Investigators

Sponsor: Ipsen

  • Ipsen Medical Director, STUDY_DIRECTOR, Ipsen

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-30
Study Completion Date2027-11

Study Record Updates

Study Start Date2025-06-30
Study Completion Date2027-11

Terms related to this study

Additional Relevant MeSH Terms

  • Cervical Dystonia